Aurobindo Pharma has rallied 6% to Rs 525 after reporting over four-fold jumped in consolidated net profit at Rs 417 crore for the third quarter ended December 31, 2013 (Q3) on back of strong operational income. The pharmaceutical company had profit of Rs 92 crore in the same quarter previous fiscal.
The company’s total income rose 36% year-on-year (yoy) at Rs 2,144 crore as compared with Rs 1,576 crore in the corresponding quarter previous year while the expenditure went up 14.64% to Rs 1,573 crore from Rs 1,372 crore in the year ago period.
The grow was mainly driven by the US formulations, which grew by 81.4% yoy, along with the ARV and EU formulation sales, which posted a yoy growth of 25.4% and 36.6% yoy respectively.
The stock opened at Rs 530 and touched a record high of Rs 540 on the NSE. A combined 3.4 million shares changed hands on the counter so far on the BSE and NSE.
The company’s total income rose 36% year-on-year (yoy) at Rs 2,144 crore as compared with Rs 1,576 crore in the corresponding quarter previous year while the expenditure went up 14.64% to Rs 1,573 crore from Rs 1,372 crore in the year ago period.
The grow was mainly driven by the US formulations, which grew by 81.4% yoy, along with the ARV and EU formulation sales, which posted a yoy growth of 25.4% and 36.6% yoy respectively.
The stock opened at Rs 530 and touched a record high of Rs 540 on the NSE. A combined 3.4 million shares changed hands on the counter so far on the BSE and NSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%